Our IsoPet® division is focused on bringing RadioGel™ Yttrium-90 brachytherapy products to veterinary oncologists to treat dogs, cats and horses suffering from
Initial treatments were coordinated through the Chair of the company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos. There are over 150 million pet dogs and cats, with over 1/3 of
the households in the US owning at least one dog, and just under 1/3 owning at least one cat.
Dr. Alice Villalobos stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of
companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as
IsoPet® (RadioGel™ Y-90) brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product
line for the treatment of accessible and inoperable tumors."
Our IsoPet® division is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product
awareness and education to veterinary oncologists.
CEO | President Mike Korenko stated: “IsoPet® allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary
space. We believe that IsoPet® is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Learn more about IsoPet's® first companion animal treatments through a study at Washington State
University funded by the Washington State Life Sciences Discovery Fund for the treatment of feline sarcoma.